Live to 150? Jim Mellon and the crew at Juvenescence just raised $46M more to give it a try
With his 62nd birthday looming next month, the science of anti-aging isn’t just another throw of the dice for British investor Jim Mellon.
“We could do with the technology ourselves,” he says on behalf of the experienced execs leading Juvenescence, Mellon’s upstart biotech venture. And he’s not just thinking about another good 40 or 50 years. Instead, he and the Juvenescence team are talking about moving the goal posts of life to 150, cracking the biological barriers that have formed a brick wall at 120.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.